061 What factors predict good patient experiences of switching from reference etanercept to an etanercept biosimilar in a South West London general hospital?

Attipoe, Laura; Patel, Samir; Birt, Robin; Crooks, Jennifer; Hunt, Kate; Grigoriou, Antigoni

doi:10.1093/rheumatology/key075.285

Cited by 4 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 In a single switch study from etanercept RP to SB4 in patients with rheumatic disease, 39% of patients experienced side effects. 59 The authors underlined the need to improve the patients' experience of switching as a way to decrease side effects. 59 This need was echoed in a single switch from etanercept RP to SB4 in patients with rheumatic disease in a single center in France.…”

Section: Etanerceptmentioning

confidence: 99%

“…59 The authors underlined the need to improve the patients' experience of switching as a way to decrease side effects. 59 This need was echoed in a single switch from etanercept RP to SB4 in patients with rheumatic disease in a single center in France. 60 Approximately 17% of patients discontinued the biosimilar, whereas no objective parameter concluded a lower efficacy or a REVIEW decreased safety profile.…”

Section: Etanerceptmentioning

confidence: 99%

See 1 more Smart Citation

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review

Barbier

Ebbers

Declerck

et al. 2020

Clin Pharma and Therapeutics

111

102

View full text Add to dashboard Cite

To date, no consensus exists among stakeholders about switching patients between reference biological products (RPs) and biosimilars, which may have been curbing the implementation of biosimilars in clinical practice. This study synthesizes the available data on switching and assesses whether switching patients from a RP to its biosimilar or vice versa affects efficacy, safety, or immunogenicity outcomes. A total of 178 studies, in which switch outcomes from a RP to a biosimilar were reported, was identified. Data were derived from both randomized controlled trials and real‐world evidence. Despite the limitations stemming from a lack of a robust design for most of the studies, the available switching data do not indicate that switching from a RP to a biosimilar is associated with any major efficacy, safety, or immunogenicity issues. Some open‐label and observational studies reported increased discontinuation rates after switching, which were mainly attributed to nocebo effects. Involvement of the prescriber in any decision to switch should remain and attention should be paid to the mitigation of a potential nocebo effect.

show abstract

Section: Etanerceptmentioning

confidence: 99%

Section: Etanerceptmentioning

confidence: 99%

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review

Barbier

Ebbers

Declerck

et al. 2020

Clin Pharma and Therapeutics

111

102

View full text Add to dashboard Cite

show abstract

“…This fact is highlighted by the finding reported by Attipoe et al, in which 21% of patients stated that their transition experience would have improved if having been given more information about the biosimilar treatment they were being switched to. 36 Furthermore, Al Tabaa et al conclude that the likelihood of patients transitioning to a biosimilar treatment was mainly related to the behavior of the physicians; and that, when using an open study design, a larger proportion of patients transitioning to a biosimilar treatment complained of lower efficiency and/or a worse safety profile. 34 Scherlinger et al also suggest that negative patient perceptions of biosimilars impact the persistence with biosimilar treatment, as shown by the lack of objective clinical disease activity among a large proportion of patients who requested to be transitioned back to the originator treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Four studies on patients with IA presented direct, patientreported data on patient experience of switching treatment. 27,36,57,77 All four studies deployed a ranking tool, the results of which are summarized in Table 2. While the ranking categories used differed between studies, the majority of patients reported a neutral or positive switching experience across studies.…”

Section: Directly Reported Patient Experience Of Switchingmentioning

confidence: 99%

“…Among the studies including patients with IA, 21 studies included some form of PRO, 18,20,21,23,24,27,[29][30][31]36,48,49,54,57,59,65,75,77,78,80,84 of which 10 studies reported PROs prior to the switch only and therefore did not provide any information on the patient experience of switching treatment. 20,21,23,24,[29][30][31]49,59,78 The PRO measurement tools used are summarized in Figure 3.…”

Section: Indirectly Reported Patient Experience Of Switchingmentioning

confidence: 99%

See 1 more Smart Citation

<p>Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review</p>

Luttropp¹,

Dalén²,

Svedbom³

et al. 2020

PPA

View full text Add to dashboard Cite

Purpose: To obtain an up-to-date overview of the measurement of patient experience of switching biologic treatment in patients with inflammatory arthritis (IA) or ulcerative colitis (UC). Secondary objectives included summarizing the types of patient-reported outcomes (PROs) used (if any), and related findings; and summarizing medical and non-medical reasons for treatment switch and/or discontinuation. Methods: A systematic literature review (SLR) was performed, searching Medline and Embase for relevant publications. Results: In total, 70 relevant publications were identified. While the majority of these reported reasons for switching and/or discontinuing treatment, only four provided information explicitly regarding patient-reported experience of switching biologic treatment. All four utilized ranking tools to assess patient experience of switching biologic treatment. The most common reason for switching and/or discontinuing treatment was loss of efficacy, while the least common reason was patient preference. Conclusion: Although the number of available treatments in IA and UC have increased, there is a sparsity of information regarding patient-reported experience of switching biologic treatment. Further research regarding patient preference and/or experience would benefit this therapeutic area and help guide treatment choices.

show abstract

Lessons from the International Experience with Biosimilar Implementation: An Application of the Diffusion of Innovations Model

Khan

Luig

Mosher

et al. 2020

hcpol

View full text Add to dashboard Cite

Although biosimilars offer cost savings in Canadian healthcare, uptake is low. We discuss the literature on international experiences with biosimilar adoption in the context of the Diffusion of Innovations model. We highlight potential challenges with biosimilar implementation and gaps in research needed to inform implementation efforts. We observe a lack of systematic description of implementation design and evaluation and a paucity of in-depth and engaged research to understand stakeholders' pragmatic considerations and the knowledge, messages and meanings that shape clinician and patient decisions to choose biosimilars. Résumé Bien que les biosimilaires permettent d'épargner des coûts pour les services de santé au Canada, leur adoption demeure faible. Nous commentons la littérature sur l' expérience internationale en matière d' adoption des biosimilaires au moyen du modèle de diffusion des innovations. Nous dégageons les défis potentiels quant à leur mise en oeuvre et nous faisons état des lacunes en matière de recherche nécessaire pour éclairer les efforts de mise en oeuvre. Nous observons un manque de description systématique des modèles de mise en oeuvre et d'évaluation ainsi qu' une rareté de recherche approfondie pour comprendre les considérations pragmatiques des intervenants ainsi que les connaissances et les messages qui éclairent les décisions prises par les cliniciens et les patients au sujet des biosimilaires.

show abstract

061 What factors predict good patient experiences of switching from reference etanercept to an etanercept biosimilar in a South West London general hospital?

Cited by 4 publications

References 0 publications

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review

<p>Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review</p>

Lessons from the International Experience with Biosimilar Implementation: An Application of the Diffusion of Innovations Model

Contact Info

Product

Resources

About